Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD
Status:
Completed
Trial end date:
2018-06-12
Target enrollment:
Participant gender:
Summary
This study's primary objective is to compare the efficacy and tolerability of switching
patients with inadequate relief on generic SSRIs to levomilnacipran versus adding a new
treatment (quetiapine) to the participants' existing treatment with people diagnosed with
depression (major depression disorder).
The secondary objective is to examine the response and remission rates following the switch
from a generic SSRI to levomilnacipran ER and augmentation with quetiapine along with
examining changes in neurocognitive and apathy measures after the switch.
Phase:
Phase 3
Details
Lead Sponsor:
Duke University
Collaborators:
Forest Laboratories Institute for Advanced Medical Research, Alpharetta, GA